Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 25

1.

Baseline characteristics of participants in the Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) Trial.

Bostom AG, Carpenter MA, Hunsicker L, Jacques PF, Kusek JW, Levey AS, McKenney JL, Mercier RY, Pfeffer MA, Selhub J; FAVORIT Study Investigators.

Am J Kidney Dis. 2009 Jan;53(1):121-8. doi: 10.1053/j.ajkd.2008.08.010. Epub 2008 Nov 20.

2.

Clinical use and rational management of homocysteine, folic acid, and B vitamins in cardiovascular and thrombotic diseases.

Stanger O, Herrmann W, Pietrzik K, Fowler B, Geisel J, Dierkes J, Weger M.

Z Kardiol. 2004 Jun;93(6):439-53. Review.

PMID:
15252738
3.

The effect of folic acid based homocysteine lowering on cardiovascular events in people with kidney disease: systematic review and meta-analysis.

Jardine MJ, Kang A, Zoungas S, Navaneethan SD, Ninomiya T, Nigwekar SU, Gallagher MP, Cass A, Strippoli G, Perkovic V.

BMJ. 2012 Jun 13;344:e3533. doi: 10.1136/bmj.e3533. Review.

4.

DACH-LIGA homocystein (german, austrian and swiss homocysteine society): consensus paper on the rational clinical use of homocysteine, folic acid and B-vitamins in cardiovascular and thrombotic diseases: guidelines and recommendations.

Stanger O, Herrmann W, Pietrzik K, Fowler B, Geisel J, Dierkes J, Weger M; DACH-LIGA Homocystein e.V.

Clin Chem Lab Med. 2003 Nov;41(11):1392-403. Review. Erratum in: Clin Chem Lab Med. 2004 Jan;42(1):113-6.

PMID:
14656016
5.

Interventions for lowering plasma homocysteine levels in dialysis patients.

Nigwekar SU, Kang A, Zoungas S, Cass A, Gallagher MP, Kulshrestha S, Navaneethan SD, Perkovic V, Strippoli GF, Jardine MJ.

Cochrane Database Syst Rev. 2016 May 31;(5):CD004683. doi: 10.1002/14651858.CD004683.pub4. Review.

PMID:
27243372
6.

Interventions for lowering plasma homocysteine levels in kidney transplant recipients.

Kang A, Nigwekar SU, Perkovic V, Kulshrestha S, Zoungas S, Navaneethan SD, Cass A, Gallagher MP, Ninomiya T, Strippoli GF, Jardine MJ.

Cochrane Database Syst Rev. 2015 May 4;(5):CD007910. doi: 10.1002/14651858.CD007910.pub2. Review.

PMID:
25938479
7.
8.

Antioxidants for chronic kidney disease.

Jun M, Venkataraman V, Razavian M, Cooper B, Zoungas S, Ninomiya T, Webster AC, Perkovic V.

Cochrane Database Syst Rev. 2012 Oct 17;10:CD008176. doi: 10.1002/14651858.CD008176.pub2. Review.

PMID:
23076940
9.
10.

Homocysteine lowering and cardiovascular disease risk: lost in translation.

Marcus J, Sarnak MJ, Menon V.

Can J Cardiol. 2007 Jul;23(9):707-10. Review.

11.

Homocysteine and renal disease.

van Guldener C, Robinson K.

Semin Thromb Hemost. 2000;26(3):313-24. Review.

PMID:
11011849
12.

Effect of folic acid supplementation on the progression of carotid intima-media thickness: a meta-analysis of randomized controlled trials.

Qin X, Xu M, Zhang Y, Li J, Xu X, Wang X, Xu X, Huo Y.

Atherosclerosis. 2012 Jun;222(2):307-13. doi: 10.1016/j.atherosclerosis.2011.12.007. Epub 2011 Dec 9. Review.

PMID:
22209480
13.

Homocysteine-lowering trials for prevention of cardiovascular events: a review of the design and power of the large randomized trials.

B-Vitamin Treatment Trialists' Collaboration.

Am Heart J. 2006 Feb;151(2):282-7. Review.

PMID:
16442889
14.

Is folate a promising agent in the prevention and treatment of cardiovascular disease in patients with renal failure?

De Vriese AS, Verbeke F, Schrijvers BF, Lameire NH.

Kidney Int. 2002 Apr;61(4):1199-209. Review.

15.

Total homocysteine concentration and associated cardiovascular and renal implications in adults.

Bergen C, Compher C.

J Cardiovasc Nurs. 2006 Jan-Feb;21(1):40-6. Review.

PMID:
16407736
16.
17.

Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality: Meta-analysis of 8 randomized trials involving 37 485 individuals.

Clarke R, Halsey J, Lewington S, Lonn E, Armitage J, Manson JE, Bønaa KH, Spence JD, Nygård O, Jamison R, Gaziano JM, Guarino P, Bennett D, Mir F, Peto R, Collins R; B-Vitamin Treatment Trialists' Collaboration.

Arch Intern Med. 2010 Oct 11;170(18):1622-31. doi: 10.1001/archinternmed.2010.348. Review.

PMID:
20937919
18.

Treatment of hyperhomocysteinemia in end-stage renal disease.

Shemin D, Bostom AG, Selhub J.

Am J Kidney Dis. 2001 Oct;38(4 Suppl 1):S91-4. Review.

PMID:
11576930
19.

Cardiovascular disease in patients with chronic kidney disease. A clinical review.

Kaisar M, Isbel N, Johnson DW.

Minerva Urol Nefrol. 2007 Sep;59(3):281-97. Review.

PMID:
17912225
20.

Homocysteine-lowering trials for prevention of vascular disease: protocol for a collaborative meta-analysis.

Clarke R, Armitage J, Lewington S, Collins R; B-Vitamin Treatment Trialists' Collaboration.

Clin Chem Lab Med. 2007;45(12):1575-81. doi: 10.1515/CCLM.2007.346. Review.

PMID:
18265450

Supplemental Content

Support Center